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Key points: Steward participation in implementation and development of 
comparative antimicrobial use visualization tools and monthly learning 
collaboratives were associated with reductions in inpatient total and anti-
pseudomonal antimicrobial use at eight Veterans Affairs (VA) facilities 
relative to the rest of the VA.
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Abstract:
Background: Antimicrobial stewards may benefit from comparative data to 
inform interventions that promote optimal antimicrobial use in the inpatient 
setting.
Methods: Antimicrobial stewards from eight geographically dispersed 
Veterans Affairs (VA) inpatient facilities participated in the development of 
iterative antimicrobial use visualization tools that allowed for comparison to 
facilities of similar complexity. The visualization tools consisted of an 
interactive web-based antimicrobial dashboard and, later, a standardized 
antimicrobial usage report updated at user-selected intervals.  Following tool
implementation, stewards participated in monthly learning collaboratives. 
The percent change in average monthly antimicrobial use [all antimicrobial 
agents, anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA), 
and anti-pseudomonal agents] was analyzed using a pre-post (1/2014-
1/2016 versus 7/2016-1/2018) design with segmented regression and 
external comparison with uninvolved control facilities (n=118).
Results: Intervention sites demonstrated a 2.1% decrease (95% confidence 
interval (CI) [-5.7%, 1.6%]) in total antimicrobial use pre-post intervention, 
versus a 2.5% increase (95% CI [0.8%, 4.1%]) in non-intervention sites 
(absolute difference 4.6%, P=0.025). Anti-MRSA antimicrobial use decreased 
11.3% (95% CI [-16.0%, -6.3%]) at intervention sites versus a 6.6% decrease 
(95% CI [-9.1%, -3.9%]) at non-intervention sites (absolute difference 4.7%, 
P=0.092). Anti-pseudomonal antimicrobial use decreased 3.4% (95% CI [-
8.2%, 1.7%]) at intervention sites versus a 3.4% increase (95% CI [0.8%, 
6.5%]) at non-intervention sites (absolute difference 7.0%, P=0.018). 
Conclusions: Comparative data visualization tool use by stewards in a pilot 
implementation project at eight VA facilities was associated with significant 
reductions in overall antimicrobial and anti-pseudomonal use relative to 
uninvolved facilities. 
Introduction:
Inappropriate antimicrobial prescribing, which accounts for 30-50% of 
all use, is a major driver of increased antimicrobial resistance, Clostridioides 
difficile infection, and other adverse events and unnecessary health care 
costs (Fridkin vital signs PMID 24598596; Fleming-Dutra JAMA PMID 
27139059).  Antimicrobial stewardship programs (ASPs) strive to improve 
antimicrobial use by encouraging evidence-based decisions regarding choice 
and duration of therapy [1].  
Antimicrobial stewards have long lacked the ability to compare their 
antibiotic usage to either national norms or to comparable facilities.  In this 
regard, the development of Standardized Antimicrobial Administration Ratios
(SAARs) within the Antimicrobial Use (AU) Option of the National Health 
Safety Network (NHSN) by the Centers for Disease Control (CDC) has been a 
major advance.  These reports provide participating sites with facility-level 
measures of days of therapy per 1000 patient days present (DOT/1000 DP) 
and utilize indirect standardization techniques to represent antimicrobial use 
data as observed to expected ratios based on CDC modeling criteria [2].  
However, the NHSN reports do not provide direct information regarding 
where an institution’s antimicrobial use lies in relation to similar facilities and
do not demarcate antimicrobial use according to specific diagnoses or across
the temporal course of therapy from initiation of empiric therapy through de-
escalation and subsequent discharge.  Such information as to how (vs. how 
much) antibiotics are used can supplement information regarding antibiotic 
usage patterns. 
To address this information gap, we extended previous projects [3,4] 
that extracted inpatient antimicrobial use data from the VA’s Corporate Data 
Warehouse (CDW) to develop a suite of interactive graphic tools that provide
stewards with in-depth facility-level reports of antibiotic use.  Antimicrobial 
use at the dashboard user’s (e.g. steward’s) facility can be compared to all 
VA facilities or user-selected facilities of similar complexity levels, and plots 
of the system-wide variability of antimicrobial use are provided.  We pilot 
tested the usability of these graphic tools and assessed their impact on three
important antimicrobial use metrics at eight VA healthcare facilities.  
Methods:
Electronic antimicrobial graphic tool development:
Specifying targeted infectious diseases and creating a framework for 
inpatient antimicrobial time course 
We initially constructed the antimicrobial use displays according to two
dimensions: disease and time frame within hospitalization. For the disease 
dimension, we focused on three common infectious conditions: Pneumonia, 
Urinary tract infection, and Skin/soft tissue infection (PUS). Diagnoses were 
determined by International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM)[5] and cross-mapped ICD-10-CM codes7 for 
each infectious process at hospital admission and discharge, as identified by 
a combination of (1) those identified previously in the literature [7], and (2) 
those identified by finding the descendants of all infections identified in the 
Systematized Nomenclature of Medicine--Clinical Terms (SNOMED CT) [8].  
Antimicrobial prescribing for each PUS diagnosis was classified within a
time-based framework corresponding to important branch points in 
antimicrobial decision-making that we termed Choice, Change, and 
Completion (CCC). Choice (i.e., the time during which decision-making 
centers around initial choice of empiric therapy) corresponded to the day of 
admission (day zero) followed by the next two calendar days of 
hospitalization (days 1-2). Change (i.e., the time in which antimicrobial 
therapy can be changed (de-escalated) based on microbiologic and other 
clinical data [9]) corresponded to days 3 and 4 of hospitalization.  
Completion (i.e., the time in which antibiotic selection is finalized and length 
of therapy is determined) corresponded to days 5 and 6 of hospitalization. 
Admission diagnoses were used to define PUS conditions to be included in 
Choice, while discharge diagnoses were used to define PUS conditions in 
Change and Completion. An additional measure termed duration of total 
antimicrobial therapy (DAT) included the entire course (inpatient and 
outpatient) of antimicrobial treatment if the PUS diagnosis was assigned at 
admission and discharge; this included the duration of inpatient therapy as 
well as the days supplied upon discharge.  Validation of data capture for the 
Choice/Change/Completion-PUS framework was conducted via chart review 
at three of the intervention sites.  At each site, one month of cases in which 
a PUS diagnosis was identified were reviewed to ensure that antimicrobial 
therapy was captured appropriately in each CCC category.  This validation 
uncovered occasional discrepancies that were clarified and refined in our 
coding.  
Interactive antimicrobial graphic tool development, implementation, 
and evolution:
The first iteration of the antimicrobial graphic tools consisted of a web-
based dashboard consisting of three interactive modules focusing on: a) 
overall trends in antimicrobial DOT/1000 DP, b) comparison of a single 
facility’s SAARs to other facilities, and c) the proportion of patients receiving 
specific antibiotics at each of the CCC intervals for PUS diagnoses.  Stewards 
had the ability to track their facility’s antimicrobial use (overall, by class of 
drug, by SAAR category, by individual agent) according to month, quarter, or
year stratified by ward type (medical/surgical ward versus intensive care 
unit). The second module showed the facility’s SAARs on a bar graph as 
compared to other VA facilities that were sharing NHSN AU data, stratified by
VA facility complexity [10].  The final module allowed stewards to see the 
frequency of their facility’s use of any individual antimicrobial agent 
compared to all other VA facilities on the Choice/Change/Completion 
spectrum for PUS diagnoses in a box-and-whiskers plot, with the ability to 
stratify according to VA facility complexity and ward type (Figure 1). 
The initial antimicrobial dashboards were implemented over an 
approximate 5-month time frame, between February and June 2016 at eight 
VA facilities recruited by the investigators. Implementation at each site 
included a visit from study team members, with a kick-off lecture to medical 
staff promoting antimicrobial stewardship. We sought to involve at least one 
physician and one pharmacist steward at each site.  Stewards were given 
data-viewing privileges specific to their institution prior to the site visit but 
were provided with additional instruction during the visit including how the 
data could be used to prioritize development of new stewardship 
interventions. 
All eight sites subsequently underwent qualitative usability 
assessments of stewards’ interactions with the antimicrobial dashboards via 
semi-structured interviews. Interviews focused on four areas: 1) the overall 
approach to stewardship of each ASP as well as types of stewardship 
activities; 2) a description of a specific experience using the antimicrobial 
dashboards; 3) user’s perceived self-efficacy and knowledge regarding the 
concepts of Choice, Change and Completion, and 4) user’s perceptions of 
usefulness and usability of the dashboards [11]. 
We held monthly learning collaborative calls with stewards and 
solicited feedback on how to improve the usability and interpretability of 
dashboard outputs.  Stewards also shared “lessons learned” regarding 
effective use of the information gleaned from the antimicrobial use displays. 
Based on feedback received through qualitative interviews and the 
monthly collaboratives we added several features to visual displays of 
antimicrobial trends, including facility-specific administration of the following
antimicrobial groups: 1) the 5 most commonly prescribed agents at the 
facility, 2) broad Gram-negative rod (GNR), 3) anti-staphylococcal, 4) anti-
pseudomonal β-Lactams & anti-MRSA, 5) fluoroquinolone, and 6) antifungal 
therapies.  Each display combined a line/bar graph of the facility’s quarterly 
antimicrobial use over a 5 year period on the right side of the screen (with 
the ability to select any combination of intensive care unit (ICU), 
medical/surgical ward, and/or Community Living Center (i.e., VA nursing 
home), and a comparator graph on the left which displays aggregate VA-
wide usage by selected facility complexity level (Figures 2a-c).  Other 
dashboard tabs allow stewards to compare their facility’s antimicrobial use 
by SAAR category (Figure 2d), CCC, and DAT for PUS conditions to all high-
complexity (level 1A) VA facilities.  Furthermore, the Pyramid Analytics 
(Kirkland, WA) platform allows for exportation of data into Microsoft Excel 
and graphs into figures that could be downloaded by stewards for 
presentation or local manipulation.  
Standardized antimicrobial use report development:
In 2017 the interactive platform was supplemented by the 
development of pre-programmed static reports of antimicrobial use that 
retained many of the interactive dashboards’ data comparisons. The pre-
programmed version, though, allowed for updated reports to be 
automatically sent to stewards at user-defined intervals. When stewards 
signed up to receive the report, they had the ability to choose the complexity
level of facilities to which their site would be compared and the frequency 
with which and to whom the report is emailed.  A sample static report, 
including a page on definitions is included as Appendix A.
Analysis of impact of program on antimicrobial use:
While local stewards were free to choose local interventions regarding 
what they perceived as their most pertinent antimicrobial usage issues, our 
analysis focused on three metrics that we hypothesized would be most 
affected by stewards’ activities in using the graphic displays: 1) total 
inpatient use of all antimicrobials; 2) anti-MRSA agents (ceftaroline, 
dalbavancin, daptomycin, linezolid, oritavancin, quinupristin-dalfopristin, 
tedizolid, telavancin, intravenous vancomycin); and 3) anti-pseudomonal 
agents (amikacin, aztreonam, cefepime, ceftazidime, doripenem, gentamicin,
imipenem-cilastatin, meropenem, piperacillin-tazobactam, tobramycin). 
For these metrics, antimicrobial usage was calculated per DOT/1000 
DP. Change in antimicrobial use over time was assessed with interrupted 
time series analysis pre- (January 2014 through January 2016) and post-
intervention (July 2016 through January 2018), allowing for the 5-month 
implementation phase in between segments. We used generalized 
estimation equations with Poisson distribution to estimate the percentage 
difference in average monthly antimicrobial use rate between segments as a 
function of the intervention phase and intervention site indicator.  
Comparisons across facilities were conducted by aggregating data from the 
eight facilities and then analyzing these in relation to aggregated use across 
all other VA facilities providing acute care services at an assigned complexity
level that had available antimicrobial use data (n=118). 
Results:
Steward insights and utility gained from the program:
During monthly collaborative calls, we asked stewards what specific 
insights and interventions where derived from interrogating the interactive 
graphic tools (selected examples in Table 1). Multiple sites focused on high 
utilization of anti-MRSA and anti-pseudomonal agents, especially during the 
Choice treatment phase and on the intensive care unit and surgical wards, 
prompting consideration of procalcitonin testing and timeout/reminder 
programs to encourage de-escalation. Fluoroquinolone usage and duration of
therapy were other themes.  One site that noted relatively high 
fluoroquinolone use and durations of therapy that prompted development of 
order sets that de-emphasized fluoroquinolones and creation of urinary 
antibiograms to assist with non-fluoroquinolone selection for UTI; a follow-up 
medication use evaluation at this site noted this intervention to be 
successful. Another site that had already transitioned much of its 
fluoroquinolone and antipseudomonal use to ceftriaxone used the tools to 
identify opportunities to de-escalate to narrower beta-lactams.  Stewards 
also reported using different data reports in informal interactions with 
stakeholders (hospitalists, intensivists, surgeons, pharmacists, medical 
trainees) across their institutions.  They also created reports and/or 
presented data to formal committees within their facility (e.g., Pharmacy & 
Therapeutics, Infection Control, and Clinical Executive Boards). Throughout 
the post-intervention period where outcomes were assessed, participation in 
the monthly collaborative calls was 83% across all sites (range 65-100%).  
Pharmacists were the primary participants from 3 sites, physicians were 
primary participants from two sites, and pharmacists and physicians 
participated equally from 3 sites.
Changes in antimicrobial usage at program sites versus the rest of VA:
Intervention sites included seven level 1 and one level 2 complexity 
sites and had a median inpatient bed size of 151 (range 37-324), with a 
median ICU census of 14.4 (range 3.6 to 24.9) and medical-surgical bed size 
of 119.5 (range 37 to 246).  The VA as a whole had a median inpatient bed 
size of 84 (range 4 to 367) with a median ICU census of 8.9 (range 1.0 to 
26.9) and medical-surgical bed size of 76.5 (range 4 to 246).  Changes in 
average monthly antimicrobial use at intervention and non-intervention VA 
facilities pre- and post-intervention are shown in Table 2.  Intervention sites 
averaged a 2.1% decrease (95% CI [-5.7%, 1.6%], p=0.2529) in total 
antimicrobial use while non-intervention sites averaged a 2.5% increase 
(95% CI [0.8%, 4.1%], p=0.0026) in use pre- vs. post-intervention. The 4.6% 
absolute difference in change between intervention and non-intervention 
sites was statistically significant (P=0.025). 
With regard to anti-MRSA antimicrobial use, intervention sites had an 
average 11.3% (95% CI [-16.0%, -6.3%], p<0.0001) decrease and non-
intervention sites had an average 6.6% decrease (95% CI [-9.1%, -3.9%], 
P<0.0001) in anti-MRSA antimicrobial use pre- vs. post-intervention; the 
4.7% change between the intervention and non-intervention sites showed 
only a statistical trend for significance (P=0.092).
Finally, intervention sites had an average 3.4% (95% CI [-8.2%, 1.7%], 
p=0.185) decrease in anti-pseudomonal antimicrobial use while non-
intervention sites had an average 3.6% increase (95% CI [0.8%, 6.5%], 
p=0.011); the 7.0% change between non-intervention and intervention sites 
was statistically significant (P=0.018).  We also performed a sensitivity 
analysis in which we included only level 1 complexity VA sites and excluded 
45 sites of lower complexity (levels 2 and 3) from our controls and found 
nearly identical findings across all three outcomes (data not shown). 
Variation among intervention sites in changes in antimicrobial use  
The variation in changes in total, anti-MRSA, and antipseudomonal use 
according to individual intervention sites is shown in Figure 3.  Changes were
largely consistent across sites; however, sites C and H did not observe as 
consistent reductions in antimicrobial use as the others.  Notably, site C had 
the lowest participation in the monthly collaboratives (65%) and site H 
experienced the sudden loss of its stewardship pharmacist early in the 
intervention period.
 Discussion:
We developed and deployed interactive and standardized graphic tools
at eight VA sites, allowing stewards to assess facility-level antimicrobial use 
overall, by drug class, for specific disease conditions, and over the course of 
therapy.  These tools illustrated temporal trends in use and provided detailed
comparisons with other similar VA facilities.  Despite not proscriptively 
requiring stewards to focus on specific antimicrobial use policies, we found 
reductions in overall antimicrobial and anti-pseudomonal use relative to 
uninvolved facilities as well as a large absolute decrease in anti-MRSA 
antimicrobial use. 
While we cannot directly attribute the decreases in antimicrobial use to
stewards’ use of the antimicrobial graphic tools, we hypothesize that the 
overall implementation strategy and follow-up served to activate stewards to
pursue interventions that focused on the particular needs of their facilities.  
Inability to easily get data regarding local antimicrobial use patterns has long
been recognized as a barrier to effective stewardship [12–14], and providing 
meaningful standardized metrics to individual facilities within a multihospital 
setting can be very challenging[15]. Furthermore, recent efforts to provide 
antimicrobial use data have focused on raw facility-specific numbers from 
the AU Option and standardized benchmarking data via SAAR and other 
observed-to-expected metrics [16] but do not provide comparative data 
showing inter-facility variability of antimicrobial use that may be important in
“nudging” stewards to devise interventions targeted to their facility. Rather 
than applying a “one-size-fits-all” approach to providing actionable metrics 
for ASPs, we allowed for customization of data receipt and presentation that 
can support the distinct local needs of any facility.
The most novel aspect of this work was the creation of the 
Choice/Change/Completion framework as a tool to evaluate where in the 
typical timeline of hospitalization for acute infectious conditions a facility 
may be overly broad in its antimicrobial prescribing patterns.  This 
framework thematically resembles the four moments of antibiotic decision 
making recently described by Tamma, et al: 1) “Does this patient have an 
infection that requires antibiotics?” 2) “Have I ordered appropriate cultures 
before starting antibiotics?” 3) “A day or more has passed. Can I stop 
antibiotics?” and 4) “What duration of antibiotic therapy is needed for this 
patient’s diagnosis?”[18]  Here, though, we apply a population-based 
quantitative determination of antimicrobial usage within discrete time 
frames in which decision making evolves to allow comparison of these 
decision points in aggregate across facilities as well as within a facility over 
time.  
We also capture the total duration of antimicrobial therapy prescribed 
for common infectious syndromes, including antibiotics prescribed at hospital
discharge.  The post-discharge course may be particularly ripe for 
antimicrobial stewardship interventions, as highlighted by a recent study of 
an antimicrobial stewardship intervention to reduce inappropriate 
fluoroquinolone prescription in 48 Michigan hospitals in which significant 
reductions in inpatient fluoroquinolone use were offset by twice as many new
fluoroquinolone starts after discharge [19].    
Limitations of our work include the relatively small number of sites 
involved (which were not selected at random and included the authors’ own 
sites) and the bundling of the visual tools with the learning collaborative that
does not allow for analysis of the effect of each individual component of the 
intervention.  We also utilized a relatively simple statistical analysis of pre- 
and post-intervention antimicrobial utilization in which residual confounding 
may not have been fully captured.  Furthermore, the exact relationship 
between amount of antimicrobial use and quality of infectious diseases 
management is unknown, though results from multiple VA analyses of 
antimicrobial utilization for pneumonia and other common infectious 
conditions indicate that opportunities to reduce excessive antimicrobial 
usage within the VA system remain ample [20–23]. Finally, our CCC 
paradigm only captures infections present at admission; antimicrobial 
utilization for infections acquired after hospital admission are not captured, 
and their treatment may interfere with our ability to measure antimicrobial 
usage for infections present at hospital admission if the antimicrobial course 
for the hospital-onset infection overlaps with that of the admission infection.
Anti-MRSA agent usage decreased throughout the VA over the 
timeframe of the study as compared to overall and antipseudomonal use, 
despite the fact that interventions targeting both anti-MRSA and 
antipseudomonal use have been championed by the VA Antimicrobial 
Stewardship Task Force (Kelly ICHE paper).  We noticed in a prior project that
it was easier to show sustained decreases in vancomycin use with a timeout 
intervention than for piperacillin-tazobactam (J Hosp Pharm paper).  It may 
very well be that, from a stewardship perspective, it is easier to 
operationalize discontinuation of anti-MRSA therapy (particularly in the VA 
where there is nasal colonization data that can help guide discontinuation) 
than antipseudomonal therapy.  Thus, giving stewards more nuanced 
comparative data regarding their facility’s antipseudomonal usage as was 
done in our current work may help them address this higher-hanging fruit.
In summary, while we were able to show temporal improvements in 
antimicrobial utilization in concert with our intervention, more research is 
needed on how visual graphics of population-level data can be used to 
influence prescribing patterns at a systems level.  At minimum, our work also
lends credence to the role that peer comparison can play in influencing 
prescribing changes on a facility level (in addition to what has been 
demonstrated for individual providers [24]).  More broadly, we demonstrate 
the potential value to VA and other large healthcare delivery organizations of
providing stewards with robust data on their facility’s antimicrobial 
utilization.  Finally, we hope that the Choice/Change/Completion framework 
we developed in this work can become a useful tool for antimicrobial 
stewardship clinical and research communities interested in defining 
opportunities for improved prescribing across the time course of inpatient 
hospitalization.
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Table 1: Examples of areas for potential improvement identified by 
stewards and interventions considered or developed
Area for improvement Intervention
High utilization of anti-
MRSA and anti-
pseudomonal agents at 
Choice 
a) Introduction of serial procalcitonin testing 
for patients with suspected sepsis or lower 
respiratory tract infection
b) Timeout program to encourage de-
escalation
High fluoroquinolone 
utilization
a) Creation and evaluation of treatment 
pathways and order sets that de-emphasize 
fluoroquinolone use
b) Creation of urinary antibiogram to assist in 
selection of non-fluoroquinolone options
Anti-pseudomonal agent 
utilization in SSTI
Pilot program in which providers who use anti-
pseudomonal agents for SSTI are emailed 
reminders as to the proper indications for 
their use in SSTI
Excessive duration of 
therapy
Development of syndrome-specific treatment 
pathways
 
Table 2: Changes in average monthly antimicrobial use (DOT/1000 DP) at intervention and non-
intervention VA facilities pre- and post-intervention
Intervention sites (n=8) Non-intervention sites (n=118)
Differen
ce
p-
valu
ePre
95
%
CI*
Pos
t
95
%
CI
%
chang
e
p-
value Pre
95
%
CI
Pos
t
95
%
CI
%
chang
e
p-
value
Total
53
3
474
-
599 522
471
-
578 -2.1% 0.25
54
8
526
-
572 562
541
-
583
+2.5
% 0.0026 -4.6%
0.02
5
Anti-MRSA
10
2
79-
132 91
71-
97
-
11.3%
<0.00
01
10
5
97-
113 98
91-
105 -6.6%
<0.00
01 -5.2%
0.09
2
Anti-
pseudomonal
11
7
96-
143
113
92-
139 -3.4% 0.185
13
3
123
-
144 138
128
-
149
+3.6
% 0.011 -7.0%
0.01
8
*: 95% Confidence Interval
Figure 1: Example of Choice/Change/Completion box and whisker 
plots*
*: sample facility’s medical-surgical ward usage of piperacillin-tazobactam 
for pneumonia is denoted by small square; dotted line represents 50th 
percentile for all facilities compared; box represents 25th-75th percentile; 
whiskers represent 5th-95th percentile 
Figure 2: Interactive antimicrobial use dashboard examples
A: Overview/Overall Antimicrobial Use (Intensive Care Unit):*
B: Top Five Most Utilized Agents (Intensive Care Unit):
C: Pseudomonal β-Lactams and Anti-MRSA Therapy
D: Facility Variation Across SAAR Antibiotic Groups
*The yellow bars represent overall antimicrobial use (corresponding to the 
scale on the right of each figure).  The lines represent antimicrobial use in 
each CDC SAAR group (corresponding to the scale on the left of each figure)
Figure 3: Variation among intervention sites in changes in 
antimicrobial use outcomes  
Appendix A: Sample Summary Antimicrobial Use Email Report
